{"id":2524,"date":"2016-12-05T00:00:00","date_gmt":"2016-12-04T23:00:00","guid":{"rendered":"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/"},"modified":"2019-01-13T16:39:37","modified_gmt":"2019-01-13T15:39:37","slug":"05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies","status":"publish","type":"post","link":"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/","title":{"rendered":"NOXXON Pharma Announces New Preclinical Data Showing Synergy of Lead Compound NOX-A12 With Natural Killer (NK) Cell Mediated Therapies"},"content":{"rendered":"<p><strong><br \/><\/strong><\/p>\n<p><strong>THESE DATA WILL BE PRESENTED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) CONFERENCE<\/strong><\/p>\n<p><strong><br \/><\/strong><\/p>\n<p><strong>Berlin, Germany, December 5, 2016<\/strong>, NOXXON Pharma N.V. (Alternext Paris: ALNOX) a clinical-stage biopharmaceutical company primarily focused on cancer treatment, announces that it presented data at the ASH conference in San Diego, California studying the role of CXCL12 inhibition by NOX-A12 (olaptesed pegol) on Natural Killer (NK) cells in tumor stroma spheroids, a preclinical model that mimics the complexity of the tumor microenvironment. These studies showed that NOX-A12 synergizes with NK cell mediated antibody-dependent cellular cytotoxicity (ADCC). Further studies of NOX-A12 with agents working through NK cell-based therapies are warranted.<\/p>\n<p><span>Poster Title:<\/span><\/p>\n<p>CXCL12 Inhibition by NOX-A12 (Olaptesed Pegol) Synergizes&nbsp;<span>With the ADCC Activity of CD20 Antibodies by Increasing NK Cell&nbsp;<\/span><span>Infiltration in a 3D Lymphoma Model<\/span><\/p>\n<p><span><br \/><\/span><\/p>\n<p><span>Authors:<\/span><\/p>\n<p>Dirk Zboralski, Anna Kruschinski, Dirk Eulberg and Axel Vater<\/p>\n<p><span><br \/><\/span><\/p>\n<p><span>Location &amp; time:<\/span><\/p>\n<p>58th ASH Annual Meeting, San Diego, CA, USA, Abstract #3021,&nbsp;<span>Session 625 Lymphoma: Pre-Clinical \u2013 Chemotherapy and Biologic Agents:&nbsp;<\/span><span>Poster II. Sunday, December 4, 2016 from 18:00 \u2013 20:00<\/span><\/p>\n<p>The poster may be downloaded from the company\u2019s website: <a href=\"http:\/\/www.noxxon.com\/downloads\/poster\/ash2016.pdf\">http:\/\/www.noxxon.com\/downloads\/poster\/ash2016.pdf<\/a><\/p>\n<p>NOX-A12, which inhibits the key tumor microenvironment chemokine CXCL12, may be a key partner for a wide range of IO (immuno-oncology) agents. NOXXON has generated promising pre-clinical and clinical data, including recent animal data showing synergy with a checkpoint inhibitor as well as recent phase 2a trials in multiple myeloma and a second hematological cancer that showed a safety profile that supports further development and first signs of efficacy. The Company believes that additional clinical trials are warranted to investigate combinations of NOX-A12 multiple classes of IO agents including those acting on or through T-cells and NK cells.<\/p>\n<!--themify_builder_content-->\n<div id=\"themify_builder_content-2524\" data-postid=\"2524\" class=\"themify_builder_content themify_builder_content-2524 themify_builder tf_clear\">\n    <\/div>\n<!--\/themify_builder_content-->\n","protected":false},"excerpt":{"rendered":"<p>NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda\u00ae (Pembrolizumab) in panacreatic and colorectal Cancer<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NOXXON Pharma Announces New Preclinical Data Showing Synergy of Lead Compound NOX-A12 With Natural Killer (NK) Cell Mediated Therapies - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NOXXON Pharma Announces New Preclinical Data Showing Synergy of Lead Compound NOX-A12 With Natural Killer (NK) Cell Mediated Therapies - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"og:description\" content=\"NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda\u00ae (Pembrolizumab) in panacreatic and colorectal Cancer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"article:published_time\" content=\"2016-12-04T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-01-13T15:39:37+00:00\" \/>\n<meta name=\"author\" content=\"norman.krey\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"norman.krey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/\"},\"author\":{\"name\":\"norman.krey\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\"},\"headline\":\"NOXXON Pharma Announces New Preclinical Data Showing Synergy of Lead Compound NOX-A12 With Natural Killer (NK) Cell Mediated Therapies\",\"datePublished\":\"2016-12-04T23:00:00+00:00\",\"dateModified\":\"2019-01-13T15:39:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/\"},\"wordCount\":301,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"articleSection\":[\"Portfolio News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/\",\"url\":\"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/\",\"name\":\"NOXXON Pharma Announces New Preclinical Data Showing Synergy of Lead Compound NOX-A12 With Natural Killer (NK) Cell Mediated Therapies - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/#website\"},\"datePublished\":\"2016-12-04T23:00:00+00:00\",\"dateModified\":\"2019-01-13T15:39:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/dewb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NOXXON Pharma Announces New Preclinical Data Showing Synergy of Lead Compound NOX-A12 With Natural Killer (NK) Cell Mediated Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dewb.de\/en\/#website\",\"url\":\"https:\/\/dewb.de\/en\/\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"description\":\"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website\",\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dewb.de\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dewb.de\/en\/#organization\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"url\":\"https:\/\/dewb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"contentUrl\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"width\":300,\"height\":82,\"caption\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\"},\"image\":{\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\",\"name\":\"norman.krey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"caption\":\"norman.krey\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NOXXON Pharma Announces New Preclinical Data Showing Synergy of Lead Compound NOX-A12 With Natural Killer (NK) Cell Mediated Therapies - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/","og_locale":"en_US","og_type":"article","og_title":"NOXXON Pharma Announces New Preclinical Data Showing Synergy of Lead Compound NOX-A12 With Natural Killer (NK) Cell Mediated Therapies - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","og_description":"NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda\u00ae (Pembrolizumab) in panacreatic and colorectal Cancer","og_url":"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/","og_site_name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","article_published_time":"2016-12-04T23:00:00+00:00","article_modified_time":"2019-01-13T15:39:37+00:00","author":"norman.krey","twitter_card":"summary_large_image","twitter_misc":{"Written by":"norman.krey","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/#article","isPartOf":{"@id":"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/"},"author":{"name":"norman.krey","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b"},"headline":"NOXXON Pharma Announces New Preclinical Data Showing Synergy of Lead Compound NOX-A12 With Natural Killer (NK) Cell Mediated Therapies","datePublished":"2016-12-04T23:00:00+00:00","dateModified":"2019-01-13T15:39:37+00:00","mainEntityOfPage":{"@id":"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/"},"wordCount":301,"commentCount":0,"publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"articleSection":["Portfolio News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/","url":"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/","name":"NOXXON Pharma Announces New Preclinical Data Showing Synergy of Lead Compound NOX-A12 With Natural Killer (NK) Cell Mediated Therapies - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","isPartOf":{"@id":"https:\/\/dewb.de\/en\/#website"},"datePublished":"2016-12-04T23:00:00+00:00","dateModified":"2019-01-13T15:39:37+00:00","breadcrumb":{"@id":"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dewb.de\/en\/05-12-16-noxxon-pharma-announces-new-preclinical-data-showing-synergy-of-lead-compound-nox-a12-with-natural-killer-nk-cell-mediated-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/dewb.de\/en\/"},{"@type":"ListItem","position":2,"name":"NOXXON Pharma Announces New Preclinical Data Showing Synergy of Lead Compound NOX-A12 With Natural Killer (NK) Cell Mediated Therapies"}]},{"@type":"WebSite","@id":"https:\/\/dewb.de\/en\/#website","url":"https:\/\/dewb.de\/en\/","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","description":"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website","publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dewb.de\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dewb.de\/en\/#organization","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","url":"https:\/\/dewb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","contentUrl":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","width":300,"height":82,"caption":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG"},"image":{"@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b","name":"norman.krey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","caption":"norman.krey"}}]}},"builder_content":"","_links":{"self":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2524"}],"collection":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/comments?post=2524"}],"version-history":[{"count":1,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2524\/revisions"}],"predecessor-version":[{"id":2653,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2524\/revisions\/2653"}],"wp:attachment":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media?parent=2524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/categories?post=2524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/tags?post=2524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}